Patent · US Active

Use of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid in treating symptoms associated with rett syndrome

US9265754B2 · kind B2 · utility

0Cited by

0References

3Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Yves-Alain Barde · Munich, DE
Graeme Bilbe · Moutier, CH
Ruben DEOGRACIAS · Basel, CH
Rainer Kuhn · Bad Kötzting, DE
Tomoya Matsumoto · Ichihara, JP
Anis Khusro Mir · Wörrstadt, DE
Anna Svenja Schubart · Basel, CH

Key dates

Filing date	Dec 5, 2013
Grant date	Feb 23, 2016
Priority date	—
Expiry date	Dec 5, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (BDNF) expression.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.